



**HAL**  
open science

## **Assessment of arterial whole blood redox potential during cardiopulmonary bypass**

Vincent Pey, Marion Stephan, Pierre Gros, Cédric Dray, Fanny Bounes, Bertrand Marcheix, Vincent Minville, Anne Galinier, Anne Galinier, François Labaste

### **► To cite this version:**

Vincent Pey, Marion Stephan, Pierre Gros, Cédric Dray, Fanny Bounes, et al.. Assessment of arterial whole blood redox potential during cardiopulmonary bypass. PLoS ONE, 2025, 20 (5), pp.e0324437. <10.1371/journal.pone.0324437>. <hal-05528604>

**HAL Id: hal-05528604**

**<https://hal.science/hal-05528604v1>**

Submitted on 26 Feb 2026

**HAL** is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.



Distributed under a Creative Commons CC BY 4.0 - Attribution - International License

RESEARCH ARTICLE

# Assessment of arterial whole blood redox potential during cardiopulmonary bypass

Vincent Pey<sup>1,2\*</sup>, Marion Stephan<sup>1,3</sup>, Pierre Gros<sup>3</sup>, Cédric Dray<sup>1</sup>, Fanny Bounes<sup>1,2</sup>, Bertrand Marcheix<sup>4</sup>, Vincent Minville<sup>1,2</sup>, Anne Galinier<sup>1,5</sup>, François Labaste<sup>1,2</sup>

**1** RESTORE Research Center, University Toulouse 3-Paul Sabatier, INSERM, CNRS, EFS, ENVT, Toulouse, France, **2** Department of Anaesthesiology and Critical Care, University Hospital of Toulouse, University Toulouse 3-Paul Sabatier, **3** Laboratoire de Génie Chimique, Université de Toulouse, CNRS, INPT, UPS, Toulouse, France, **4** Department of Cardiovascular Surgery, University Hospital Rangueil, Toulouse, France, **5** Department of biochemistry, Toulouse University Hospital, Toulouse, France

\* [pey.vi@chu-toulouse.fr](mailto:pey.vi@chu-toulouse.fr)



## Abstract

### Introduction

Imbalance in the redox equilibrium is common in any type of aggression. Cardiopulmonary bypass (CPB) initiation induces metabolic perturbations, and reliable biological monitoring tools for this condition are currently limited (e.g., lactate/pyruvate ratio). The measurement of arterial whole blood redox potential ( $E_{\text{redox}}$ ) provides a systemic assessment of the redox state and may serve as a valuable marker for detecting metabolic perturbations during CPB. In this prospective exploratory study involving patients undergoing cardiac surgery, we investigated variations in  $E_{\text{redox}}$  and lactate/pyruvate ratio during CPB initiation.

### Methods

Using a prospective exploratory study design, we assessed the changes in  $E_{\text{redox}}$  and relevant variables during the initiation of CPB in 16 cardiac surgery patients.

### Results

Upon initiation of CPB we observed a significant decrease in arterial whole blood redox potential (101.90 mV +/- 11.52 vs. 41.80 mV +/- 10.26;  $p < 0.0001$ ). Concomitantly, the lactate/pyruvate ratio significantly increased (12.81 +/- 0.90 vs 67.1 +/- 7.94;  $p < 0.0001$ ) while the acetoacetate/ $\beta$ -hydroxybutyrate ratio significantly decreased (1.11 +/- 0.19 vs. 0.54 +/- 0.05 at 0 min;  $p = 0.0055$ ). The circulatory failure indicated by changes in the lactate/pyruvate ratio and ketone bodies at the initiation of CPB correlated with a significant reduction in  $E_{\text{redox}}$ .

## OPEN ACCESS

**Citation:** Pey V, Stephan M, Gros P, Dray C, Bounes F, Marcheix B, et al. (2025) Assessment of arterial whole blood redox potential during cardiopulmonary bypass. PLoS One 20(5): e0324437. <https://doi.org/10.1371/journal.pone.0324437>

**Editor:** Alaa Ramadan, South Valley University Faculty of Medicine, EGYPT

**Received:** August 8, 2024

**Accepted:** April 23, 2025

**Published:** May 27, 2025

**Copyright:** © 2025 Pey et al. This is an open access article distributed under the terms of the [Creative Commons Attribution License](https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

**Data availability statement:** The data cannot be publicly shared due to restrictions established by the Toulouse University Hospital, which is the sponsor of the study. Data transfer is possible if formalized through a contractual agreement with the Toulouse University Hospital (Mrs. Marie-Elise LLAU,

Head of the Promotion Unit at the Research Directorate. [lau.me@chu-toulouse.fr](mailto:lau.me@chu-toulouse.fr) Avenue du Professeur Jean Poulhès, 31400 Toulouse, France) for researchers who meet the criteria for access to confidential data.

**Funding:** This study has been partially supported through the grant EUR CARE N°ANR-18-EURE-0003 in the framework of the Programme des Investissements d'Avenir and EURO BIO scientific Paris.

**Competing interests:** The authors have declared that no competing interests exist.

## Conclusion

Arterial  $E_{\text{redox}}$  is a novel variable that holds promise in the detection and monitoring of metabolic aggression during CPB. Its assessment during CPB initiation could provide valuable insights into the patient's circulatory status, as the  $E_{\text{redox}}$  appears to be more sensitive than lactate for monitoring circulatory insufficiency.

## Introduction

In the operating room, patients undergo multiple insults related to surgery, anesthesia, and the adverse effects of therapeutics. Many of these insults ultimately disrupt cellular metabolism and, among other things and obligatory, the balance between oxidant and reductant species. Measuring specific markers of these imbalances, such as blood lactate levels is well established and is widely used, which refers to tissue hypoxia. However, the causes of these biologic changes can be manifold. Thus, there are non-hypoxic causes for lactate elevation, such as hepatic dysfunction, pyruvate dehydrogenase dysfunction, and accelerated glycolysis [1,2]. Moreover, lactate clearance may also be impaired even after the resolution of the underlying process. As a result, monitoring tissue hypoxia through lactate measurement may lead to misinterpretation. Thus, global redox potential ( $E_{\text{redox}}$ ) represents a novel and relevant option for monitoring tissue hypoxia.

The  $E_{\text{redox}}$  allows to evaluate the balance between oxidized and reduced species by measuring the electron charge of a complex biological environment. In an in vivo model of hemorrhagic shock in pigs, arterial  $E_{\text{redox}}$  measurement has been correlated with the severity of circulatory failure, elevation of lactate levels, and perturbation of the redox balance in the tissues [3,4]. The  $E_{\text{redox}}$ , unlike lactate, appears to be more sensitive, with a measurement dynamic correlated to the degree of circulatory failure and its management.

There are no human models in the literature that allow evaluation of  $E_{\text{redox}}$  during circulatory failure. To investigate  $E_{\text{redox}}$  variation following the circulatory failure in human, we choose the model of the initiation of CPB. Indeed, macro-circulatory and micro-circulatory disturbances during CPB initiation alter the efficiency of mitochondrial oxidative phosphorylation and promote the accumulation of reduced metabolites, such as NADH and lactate [5,6]. These metabolites impair cellular function and activate cell death programs, ultimately leading to organ dysfunction [7]. This model of programmed circulatory failure appears relevant as it allows us to measure the  $E_{\text{redox}}$  value prior to the onset of circulatory failure. Thus, our objective is to describe the evolution of arterial redox potential during CPB.

## Methods

### Study description

This was a prospective, observational, monocentric study conducted at the Cardiac Surgery Department of the University Hospital Center (CHU) of Toulouse between January and May 2022. The study was approved by an ethics committee

(NCT04907565; RC31/21/0014). Informed consent was obtained from the patients before their inclusion, as required by ethical committee and French legislation.

## Population

Patients included were over 60 years old, able to provide informed consent, and scheduled for cardiac surgery under general anesthesia requiring CPB. They were excluded if they required emergency surgery, hypothermia, circulatory arrest or surgeries linked to a septic condition.

## Research procedure

Preoperative preparation followed national recommendations and remained unchanged [8]. Upon arrival in the operating room, each patient underwent standard monitoring, as well as the placement of a central jugular venous line and a radial arterial catheter. After general anesthesia, the patient was mechanically ventilated. All surgeries were performed via sternotomy. Following patient heparinization, CPB was initiated. The blood circulating in the CPB system was warmed (37°C), oxygenated (target pO<sub>2</sub> at 140 mmHg), and gradually returned to the aorta with increasing flow through the arterial cannula. Once CPB reached the target flow rate (2.4 ml/min/m<sup>2</sup>), cardiac activity was gradually stopped (using cardioplegia consisting in hyperkalemic fresh blood). Immediate postoperative care was provided in the intensive care unit and the cardiac surgery ward, as soon as the patient's condition allowed. At the end of hospitalization, clinical data were collected.

During the procedure, 2 ml of blood were drawn from the radial arterial catheter. Blood pH, arterial oxygen saturation (SaO<sub>2</sub>), and hemoglobin concentration were immediately measured using a Siemens RP 500 blood gas analyzer. Then, the remainder of 1 ml of blood was mixed with 1 ml of 1N perchloric acid for delayed measurement of redox point (lactate, pyruvate, betahydroxybutyrate, acetoacetate) using BIOSENTEC kits on a ThermoScientific INDIKO+ analyzer.

E<sub>redox</sub> measurement was performed immediately after blood sampling with a potentiostat (μAutolab type II, Metrohm) using a single-use "lab-made" working platinum microelectrode [9] and a commercially available reference electrode (BioLogic, Seyssinet-Pariset, France). Both electrodes were immersed in the patient's arterial whole blood without pre-treatment. Data were collected for 60 seconds using the NOVA® 2.0 application with one potential value recorded per millisecond. The median, the final E<sub>redox</sub> value, is calculated from the remaining adequate potential values, expressed in millivolts.

During CPB, central venous oxygen saturation (ScVO<sub>2</sub>) was measured by oximetry on the CPB circuit. Based on these measured variables and CPB blood flow (Qc), the oxygen delivery to the tissues (DO<sub>2</sub> = Qc x 1.34 x [Hb] x SaO<sub>2</sub>), oxygen consumption (VO<sub>2</sub> = (SaO<sub>2</sub> - ScVO<sub>2</sub>) x Qc x 1.34 x [Hb]), and oxygen extraction from the tissues (EO<sub>2</sub> = VO<sub>2</sub>/DO<sub>2</sub>) were calculated.

Samples were collected after induction of general anesthesia before surgical incision (Pre-CPB), at the achievement of the target CPB flow (0 min), at 10, 20 and 30 minutes.

**Statistical analysis.** Binary variables were expressed as percentages. Continuous variables were expressed as mean and standard error. Statistical analyses were performed using GraphPAD Prism® version 8 software. Univariate statistical tests were conducted using the Mann-Whitney method for continuous variables and the Fisher's test for binary variables. A p-value < 0.05 was considered statistically significant.

## Results

### Study population

During the study period, 21 patients were included in the study. Sixteen patients had an E<sub>redox</sub> measurement during CPB. For 5 of them, a technical difficulty prevented obtaining a reliable E<sub>redox</sub>. Lactate and pyruvate measurements were performed for 14 patients with minimal missing data (3.6% - broken tubes during centrifugation, uncertain dilution factor induced by pre-analytical step).

Patient characteristics are summarized in [Table 1](#). The male-to-female ratio among the included patients was 11:5. They had a median age of approximately 71.5 years (Q1-Q3: 67.5–74 y.o.). Most surgeries were coronary artery surgeries (n=6). Four patients underwent valve surgery, and 2 had aortic surgery. Three procedures involved 2 interventions (valve replacement and bypass). The mean duration of CPB was 70.5 minutes (Q1-Q3: 54.7–80.7 min). All patients in the cohort received norepinephrine during the operation, but none of them required the addition of a postoperative inotrope or circulatory support. Two patients received transfusions during their hospitalization, none during surgery. In the postoperative period, the SAPS II score was approximately 29 (Q1-Q3: 27–37).

### **$E_{\text{redox}}$ at CPB initiation: a brief drop**

The primary objective of this research was to describe the variation in arterial whole blood  $E_{\text{redox}}$  at the initiation of CPB. Before the introduction of CPB, the  $E_{\text{redox}}$  value was homogeneous among patients with an average of 101,90 mV (+/- 11.52). We observed a significant decrease in the redox potential upon initiation of CPB (101.90 mV +/- 11.52 vs. 41.80 mV +/- 10,26;  $p < 0.0001$ ) ([Fig 1](#)). Interestingly, the redox potential returns to its baseline value at the 10-minute mark and appears to stabilize without significant difference compared to the pre-CPB value (101,90 mV +/- 11.52 vs. 113.80 +/- 14.49;  $p = 0.98$ ).

### **Lactate and ketone bodies variations at CPB initiation**

The start of CPB led to a significant increase in lactate levels at 0 min (1.05 +/- 0.11 vs 5.38 +/- 0,38 mmol/L;  $p < 0.0001$ ), and a lactate/pyruvate ratio of 12.81 (+/- 0.90) compared to 67.1 (+/- 7.94;  $p < 0.0001$ ) after circulatory support ([Fig 2](#)). The blood lactate concentration returns to its baseline value within 20 and 30 minutes after CPB initiation. The lactate/pyruvate ratio remained above the baseline value at 10 minutes (21.57 +/- 1.178 vs. 12.81 +/- 0.90;  $p = 0,034$ ).

The acetoacetate/ $\beta$ -hydroxybutyrate ratio significantly decreased during CPB initiation (1.11 +/- 0.19 in Pre-CPB vs. 0.54 +/- 0.05 at 0 min;  $p = 0.0055$ ). From 10 min to 30 min time-point, the ketone body ratio remained significant under the basal value, which is a distinctive evolution compared to other metabolic markers as lactate/pyruvate ratio and redox potential. ([Fig 2](#)).

### **Concerning main hemodynamic variables**

We observed a significant decrease in systolic blood pressure between the pre-CBP period and the 10-minute mark. Concomitantly, heart rate decreases with the administration of cardioplegia between 5 and 10 minutes after the initiation of CPB. The initiation of CPB did not have a significant impact on mean arterial pressure (76.4 mmHg +/- 4.8 vs 75.1 mmHg +/- 4.9;  $p = 0.61$ ) as the 0 min time point was measured when the target theoretical flow rate was achieved ([Fig 3a](#)). Hemoglobin levels decreased significantly by approximately 2.6 g/dl (13.1 +/- 0.3 vs 10.5 +/- 0.3) ( $p < 0.0001$ ) ([Fig 3b](#)). CPB initiation also appeared to affect skeletal muscle tissue perfusion, with a significant variation in tissue saturation absolute values: 72% +/- 1.2 before CPB vs. 69.8% +/- 1.9 at 0 min ( $p < 0.01$ ) ([Fig 3c](#)).  $DO_2$  at the 0-minute point was also significantly lower than  $DO_2$  at 30 minutes after the initiation of CPB (324.8 +/- 20.8 vs. 377.1 +/- 17.42;  $p = 0.027$ ) ([Fig 3d](#)). All measured variables are presented in [Table 2](#). Ten minutes after the initiation of extracorporeal circulation, the macrohemodynamic variables were stabilized without signs of circulatory failure.

### **Discussion**

In this study, we demonstrated that CBP initiation is associated with a significant decrease in arterial  $E_{\text{redox}}$ , and that the return to baseline was faster when monitored using the  $E_{\text{redox}}$ . We also observed an increase in the lactate/pyruvate ratio and a decrease in the acetoacetate/ $\beta$ -hydroxybutyrate ratio. The initiation of CPB led to significant macro- and micro-hemodynamic disturbances.

**Table 1. Cohort characteristics.**

	Total patients n = 16
<b>a) Preoperative Data</b>	
Age (y.o), médiane (Q1-Q3))	71.5 (67.5-74)
Sex:	
Female, No. (%)	5 (31.2)
Male, No. (%)	11 (68.7)
Weight, median (Q1-Q3))	75.5 (68.4-81.2)
BMI, median (Q1-Q3))	25,3 (23.7-28.4)
Medical History:	
Hypertension, No. (%)	12 (75)
Diabetes, No. (%)	2 (12.5)
Dyslipidemia, No. (%)	12 (75)
Steatosis, No. (%)	1 (6.2)
Atrial Fibrillation, No. (%)	1 (6.2)
COPD, No. (%)	4 (28.6)
Stroke, No. (%)	1 (6.2)
EuroSCORE II <sup>†</sup> , median (Q1-Q3))	1,5 (0.9-3.0)
Preoperative Treatments:	
ACE inhibitor or ARB, No. (%)	12 (75)
Beta-blocker, No. (%)	9 (56.2)
Aspirin, No. (%)	11 (68.7)
Metformin, No (%)	1 (6.2)
Insulin, No (%)	1 (6.2)
Statins, No (%)	13 (81.2)
Preoperative LVEF > 50%, No. (%)	15 (93.7)
<b>b) Intraoperative data</b>	
Extracorporeal Circulation:	
Total (min), median (Q1-Q3)	70.5 (54.7-80.7)
Clamping (min), median (Q1-Q3))	59.5 (4-71)
Surgery Type:	
Valve, No. (%)	4 (25)
Coronary Bypass, No. (%)	6 (37.5)
Aortic Surgery, No. (%)	2 (12.5)
Combined Surgery, No. (%)	3 (18.7)
Myxome, No. (%)	1 (6.2)
Transfusion <sup>††</sup> RBCs, No. (%)	2 (12.5)
Intraoperative treatments	77 (26)
Ketoprofen, No (%)	2 (12.5)
Dexamethasone, No (%)	13 (81.2)
Norepinephrine, No (%)	16 (100)
<b>c) Postoperative Data</b>	
SAPS II <sup>†††</sup> , median (Q1-Q3)	29 (27-37)
Peak Troponin Level (ng/l), median (Q1-Q3))	496.5 (294.5-641)
Glomerular Filtration Rate at Day 7, median (Q1-Q3))	84 (72.5-88.5)
Ventilation Duration (h), median (Q1-Q3))	6 (4-9.7)

(Continued)

Table 1. (Continued)

	Total patients n = 16
Duration of Norepinephrine Administration (h), median (Q1-Q3))	11 (3.5-25.2)
Length of ICU Stay (day), median (Q1-Q3))	3.5 (1-5)
Total Hospitalization Duration (day), median (Q1-Q3))	9 (8-10.2)

BMI: Body Mass Index; COPD: Chronic Obstructive Pulmonary Disease; LVEF: Left Ventricular Ejection Fraction; RBC: Red Blood Cells.

\*EuroSCORE II: a score used to assess the preoperative risk of cardiac surgery, subsequently yielding an estimated probability of mortality at 30 days (takes into account, among other data, age, certain medical history, critical status prior to surgery, renal function before surgery, number of previous surgeries, and number of procedures).

\*\*Transfusion is used here as a categorical variable, including both perioperative and postoperative transfusion.

\*\*\*SAPS II: Simplified Acute Physiology Score 2; a calculated score using parameters collected during the first 24 hours of intensive care. It predicts to the probability of mortality during the stay.

<https://doi.org/10.1371/journal.pone.0324437.t001>





Fig 1. Evolution of arterial redox potential during CPB. Change in arterial redox potential ( $E_{redox}$ ) during CPB in millivolts (mV) relative to the baseline value before CBP initiation (Pre-CPB). Mean and standard error.


<https://doi.org/10.1371/journal.pone.0324437.g001>

To characterize the onset of hemodynamic instability upon the initiation of CPB, we observed disturbances in macro-hemodynamic variables. It included a decrease in systolic arterial pressure (concomitant with cardioplegia), a reduction in hemoglobin levels,  $DO_2$  values at 0 minutes versus 30 minutes, and a significant decrease in tissue oxygenation. These disturbances fall within the usual ranges for the initiation of CPB [10]. In our view, they indicate that the implementation of CPB is associated with hemodynamic instability that may lead to circulatory failure in the patient's tissues [5, 11–14]. We aimed to confirm this circulatory failure by precise measurement of metabolites that are not routinely accessible but are early indicators of shock states. We regularly measured the arterial concentration of lactate, pyruvate, acetoacetate, and  $\beta$ -hydroxybutyrate. These measurements allowed us to obtain a more precise description of cytoplasmic and mitochondrial redox state. We observed a rapid disturbance of both systems upon the initiation of CPB. Firstly, we noted a significant increase in lactatemia while pyruvatemia remained stable. These results are already described in the literature [15]. A lactate/pyruvate ratio greater than 24 is associated in the literature with increased mortality in septic shock. It is a marker



**Fig 2. Changes in lactate/pyruvate ratio and ketone bodies ratio during CPB.** L/P: Arterial lactate/pyruvate ratio. Ketone bodies ratio: acetoacetate/ $\beta$ -hydroxybutyrate. CPB: cardiopulmonary bypass.

<https://doi.org/10.1371/journal.pone.0324437.g002>



**Fig 3. Changes in circulatory variables during CPB.** a) Variation in systolic and mean arterial pressure and heart rate during the initiation of CPB. b) Hemoglobin level (g/dL). c) StO<sub>2</sub> variation from baseline (Pre-CPB) measured by near-infrared spectroscopy d) Variations in DO<sub>2</sub> (oxygen transportation) et VO<sub>2</sub> (oxygen consumption) after CEC initiation; mean and standard error.

<https://doi.org/10.1371/journal.pone.0324437.g003>

of hypoperfusion [16]. During shock, the lactate/pyruvate ratio increases in the blood as well as in adipose tissue and skeletal muscle [17,18]. This indicates a metabolic shift towards anaerobic glycolysis and lactate production [19]. The impaired elimination of lactate can be also explained by a disturbance in hepatic metabolism. This explains the slower return of lactatemia to its baseline value, in contrast to the  $E_{\text{redox}}$ , which appears to be more reactive. This hypothesis seems to be supported by the decrease in the ketone ratio [20]. The literature agrees on the microcirculatory disturbances during CPB. These are reflected by the increased production of lactate, alterations in tissue saturations, impairment of arteriolar vaso-reactivity, and a decrease in the number of perfused capillaries [5,13,14,21].

The variations in the acetoacetate/ $\beta$ -hydroxybutyrate ratio are characteristic of a metabolic shift towards ketolysis and the production of acetyl-CoA [22]. This is a marker described in the literature as indicative of circulatory failure. Ketones are an alternative energy source for tissues, particularly the brain. The rapid variations in the acetoacetate/ $\beta$ -hydroxybutyrate ratio are characteristic of the onset of stress in the body [23,24]. It is also an indicator of the hepatic response to the insult. The abrupt decrease in the ratio after the initiation of CPB indicates the release of  $\beta$ -hydroxybutyrate by hepatic mitochondria. Once in the systemic circulation,  $\beta$ -hydroxybutyrate becomes a source of ATP for the tissues [22]. This decrease has been observed in several studies [25,26].

Intraoperative lactatemia is a good predictor of patient outcomes [27]. The higher it is, the greater the risk of mortality. In contrast to lactate, although ketone bodies play a role in highlighting hepatic dysfunction or hypoxic processes, they are not correlated with patient outcomes [25]. The ketone body ratio values are comparable to those found during septic shock and cardiogenic shock [28]. The decrease in the ketone body ratio below 0.4 during CPB is correlated with the elevation of transaminases postoperatively [25]. However, our study did not reach such low levels, and the patients did not exhibit elevated hepatic enzymes postoperatively.

Ultimately, we demonstrate through precise biological variables that are not accessible in routine practice that there is a phase of hemodynamic instability associated with tissue circulatory failure during the initiation of CPB. The ability to detect circulatory failure is of paramount importance for the proper monitoring of patients in the cardiac surgery operating room [29]. Therefore, we developed a system to measure the  $E_{\text{redox}}$ . The metabolic disturbances in tissues during circulatory failure are numerous and lead to the release of various metabolites. The measurement of lactatemia, which is available in routine practice, presents significant limitations [30].

The measurement of arterial whole blood  $E_{\text{redox}}$  during CPB is an innovative approach that has not been previously described in humans. We observed a marked reduction in  $E_{\text{redox}}$  during CBP initiation, with consistent patterns among patients as indicated by the observed standard deviations. The measurement of global redox state in whole blood provides a more comprehensive approach than measuring circulating metabolites, which are limited in their knowledge and subject to technological constraints. This global measurement is thus likely to be more sensitive to tissue hypoxia. Few studies have investigated  $E_{\text{redox}}$  in humans, and previous measurements have been limited to plasma samples [4,15]. Measuring only plasma  $E_{\text{redox}}$  cannot represent the systemic redox state of a patient as it disregards the redox contribution of blood cells. Red blood cells play a crucial role in the redox balance of blood. Therefore, arterial whole blood  $E_{\text{redox}}$  appears to be a promising technique for detecting and monitoring mitochondrial dysfunction induced by circulatory failure. We demonstrated that the arterial  $E_{\text{redox}}$  decreases significantly at the initiation of CPB and appears to coincide with the onset of circulatory failure. This  $E_{\text{redox}}$  rapidly returned to baseline after achieving satisfactory macrohemodynamics status. Several spectroscopic techniques, such as NIRS and  $\text{SvO}_2$ , highlight increased tissue oxygen extraction in situations of circulatory failure. However, these methods primarily reflect tissue adaptation to adverse conditions rather than direct tissue injury.

This study opens numerous perspectives for both research and potential clinical applications. The practice of anesthesia and intensive care is guided by advances in therapeutic strategies to combat tissue hypoxia, regardless of its origin. Therefore, tools for exploring the correction of redox imbalance are appealing for diagnosing and stratifying patient risk. In terms of research, adaptation of the measurement system could enable continuous monitoring of this parameter in cardiac surgery and intensive care patients, allowing continuous assessment of blood redox balance and early detection

**Table 2. Descriptive table of circulatory variables during CPB.**

	Pre-CBP	0 min	10 min	20 min	30 min	Pre-CBP vs 0 min p	Pre-CBP vs 10 min p
Biological variables							
E <sub>redox</sub> (mV)	101.9 (11.52)	41.80 (10.26)	113.80 (14.49)	80.38 (10.77)	79.02 (22.67)	<0.0001	0.98
Lactate (mmol/l)	1.05 (0.11)	5.38 (0.38)	2.30 (0.15)	1.98 (0.21)	1.82 (0.17)	<0.0001	<0.0001
Pyruvate (μmol/l)	90.92 (9.75)	90.23 (7.40)	125.5 (12.54)	109.8 (9.89)	103.0 (8.13)	>0.99	0.0217
L/P	12.81 (0.90)	67.10 (7.94)	21.57 (1.78)	17.90 (1.41)	16.28 (1.05)	0.0004	0.0045
Acetoacetate (μmol/l)	170.2 (27.3)	200.9 (41.8)	200.7 (41.8)	221.5 (49.5)	274.9 (56.6)	0.28	0.63
β-hydroxybutyrate (μmol/l)	231.2 (76.7)	498.3 (187.1)	501.9 (221.4)	514.3 (220.9)	603.8 (263.5)	0.27	0.43
Ketone ratio	1.11 (0.19)	0.53 (0.053)	0.55 (0.07)	0.75 (0.11)	0.74 (0.09)	0.0055	0.0079
Hb (g/dl)	13.06 (0.29)	10.46 (0.28)	10.93 (0.31)	11.16 (0.35)	11.63 (0.48)	<0.0001	<0.0001
Arterial Blood Glucose (mmol/l)	6.52 (0.38)	7.53 (0.53)	8.09 (0.43)	9.05 (0.55)	9.63 (2.22)	0.019	0.0029
pH	7.42 (0.01)	7.38 (0.01)	7.41 (0.01)	7.41 (0.02)	7.36 (0.01)	0.14	0.99
Hemodynamic variables							
StO <sub>2</sub> variation (% from baseline)	100	95.21 (1.42)	98.05 (0.83)	97.27 (0.91)	96.44 (0.79)	0.044	0.21
SaO <sub>2</sub> (%)	98.31 (0.24)	97.48 (0.49)	98.20 (0.24)	98.86 (0.21)	98.53 (0.18)	0.52	0.99
Bispectral Index	45.33 (2.13)	44.53 (2.56)	49.09 (4.02)	48.45 (3.74)	46.46 (2.60)	0.99	0.90
HR (bpm)	59.80 (4.73)	57.79 (9.47)	0	0	0	0.99	/
SAP (mmHg)	107.2 (7.27)	88.25 (6.74)	70.69 (3.42)	73.33 (2.29)	71.08 (2.71)	0.39	0.022
MAP (mmHg)	76.40 (4.85)	75.10 (4.94)	70.64 (3.66)	73.21 (2.25)	69.81 (2.56)	0.99	0.93
Tp (°C)	35.30 (0.18)	34.93 (0.16)	39.93 (4.29)	36.26 (0.08)	36.36 (0.13)	0.12	0.012
ScVO <sub>2</sub> (%)	/	73.73 (1.87)	77.93 (0.86)	76.64 (0.54)	76.42 (0.55)	/	/
DO <sub>2</sub> (ml/min/m <sup>2</sup> )	/	324.8 (20.8)	363.8 (18.4)	373.7 (19.5)	377.1 (17.4)	/	/
VO <sub>2</sub> (ml/min/m <sup>2</sup> )	/	72.85 (4.97)	74.51 (3.88)	82.37 (4.78)	85.62 (5.16)	/	/
EO <sub>2</sub>	/	23.52 (1.73)	20.69 (0.90)	22.00 (0.49)	22.64 (0.64)	/	/

Quantitative variables: mean (standard error); E<sub>redox</sub>: arterial redox potential; L/P: arterial lactate/pyruvate ratio; StO<sub>2</sub> variation: tissue oxygen saturation variation from baseline (Pre-CPB); SaO<sub>2</sub>: arterial oxygen saturation; Hb; hemoglobin; SAP: systolic arterial pressure; MAP: mean arterial pressure; Tp: central body temperature; Ketone bodies: acetoacetate/β-hydroxybutyrate ratio; ScVO<sub>2</sub>: central venous oxygen saturation; DO<sub>2</sub>: oxygen delivery; VO<sub>2</sub>: oxygen consumption; EO<sub>2</sub> = VO<sub>2</sub>/DO<sub>2</sub> ratio. Ketone ratio: Acetoacetate/β-hydroxybutyrate P value of ANOVA and Mann-Whitney.

<https://doi.org/10.1371/journal.pone.0324437.t002>

of circulatory failure. The technique appears to be complementary to cardiac output monitoring. Evaluating mitochondrial function would be a valuable way to assess the match between oxygen demand and transport. The E<sub>redox</sub> could enable us to identify different variability profiles not observed in this study, particularly in more severe patients. The study of E<sub>redox</sub> is meaningful only if distinct profiles exist, allowing for the proposal of therapeutic adaptations to restore tissue oxygenation. Unlike lactates, where clearance is sometimes impaired, the rapid correction of E<sub>redox</sub> could provide greater responsiveness to clinicians. These hypotheses will need to be confirmed in larger-scale studies.

E<sub>redox</sub> provide informations on the sum of electronic exchanges among all the redox couples at thermodynamic equilibrium contained in the sample. Then the whole blood redox status must be evaluated with a delocalized device easily usable in the operating room, which implies a reagentless method, without sample preparation and providing realtime results. The global tests as developed today do not meet all these requirements. Moreover, they do not consider the latency phase of certain reactions, kinetically disadvantaged with the metallic complexes, in particularly the liposolubles antioxidants such as alfatocopherol, and the intervention of redox molecules which are not antioxidant, like proteins or lipids.

The main limitation of this study is the small sample size, with only 21 patients included, of which 16 had measurements of  $E_{\text{redox}}$ . However, this study was exploratory, aiming to validate the feasibility of the technique and its correlation with lactate levels.

The patients included in the protocol had an average Euroscore II of 1.5%, which is relatively low compared to larger cohorts (3.95%) [31]. The SAPS II score was on average low at 29, compared to an average of 39 in cardiac surgery literature [32]. One patient in the cohort had type II diabetes and was on insulin and metformin. Thirteen patients were treated with statins prior to inclusion. Thus, the patients in the study presented a low risk of postoperative complications and, consequently, a low risk of mortality in the context of cardiac surgery. The patients in this study thus appeared to be less comorbid than the usual population undergoing cardiac surgery. The effects observed upon the initiation of CPB do not seem to be related to a particularly altered state of the study patients. In this preliminary study, we deliberately focused on elective surgeries. These procedures enable the measurement of redox potential without prior physiological stress. The baseline redox potential value remains undefined. In contrast, emergency surgeries carry the risk of pre-existing redox potential disturbances before the intervention.

The presence of treatments (insulin, metformin, statins) and conditions (diabetes) that could potentially alter metabolism did not affect the arterial blood  $E_{\text{redox}}$ . We hypothesize that this is due to the intensity of the insult related to the implementation of CPB. CPB profoundly disrupts tissue metabolism, as evidenced by the disturbances in lactate/pyruvate and acetoacetate/ $\beta$ -hydroxybutyrate ratios. It is established that statins may help mitigate the effects of hypoxia on tissues [33]. As expected in this population, only one patient was not on statin therapy before surgery. Their redox profile was comparable to that of the other patients. This could also be explained by the severity of the insult associated with the initiation of CPB.

The purpose of CPB is to replace the patient's blood flow, resulting in a very brief period of circulatory failure. The ideal characterization of this mismatch between oxygen supply and demand would involve continuous measurement of mixed venous oxygen saturation ( $\text{SvO}_2$ ) and cardiac output prior to CPB initiation, allowing calculation of tissue oxygen consumption. However, these measurements were not performed in this study. Nonetheless, we observed concordance among variables, suggesting that CPB initiation is indeed associated with circulatory failure (lactate/pyruvate ratio, systolic blood pressure, near-infrared spectroscopy, hemodilution, ketone bodies). The existing literature also leaves little doubt on this matter. In the future, it would be relevant to conduct similar research in other models of circulatory failure.

## Conclusion

Arterial whole blood  $E_{\text{redox}}$  is a novel variable that holds promise in the detection and monitoring of blood metabolic perturbations during CPB initiation. Its assessment during CPB initiation could provide valuable insights into the patient's circulatory status, as the  $E_{\text{redox}}$  appears to be more sensitive than lactate for monitoring circulatory insufficiency. Further larger-scale studies will be necessary to confirm the relevance of this new variable in perioperative and intensive care monitoring.

## Author contributions

**Conceptualization:** Anne Galinier, François Labaste.

**Formal analysis:** Vincent Pey.

**Investigation:** Vincent Pey, Marion Stephan.

**Methodology:** Vincent Pey.

**Supervision:** François Labaste.

**Validation:** François Labaste.

**Writing – original draft:** Vincent Pey.

**Writing – review & editing:** Vincent Pey, Marion Stephan, Pierre Gros, Cédric Dray, Fanny Bounes, Bertrand Marcheix, Vincent Minville, Anne Galinier, François Labaste.

## References

1. Bakker J, Postelnicu R, Mukherjee V. Lactate: where are we now?. *Crit Care Clin.* 2020;36(1):115–24. <https://doi.org/10.1016/j.ccc.2019.08.009> PMID: [31733674](https://pubmed.ncbi.nlm.nih.gov/31733674/)
2. Weinberger J, Klompas M, Rhee C. What is the utility of measuring lactate levels in patients with sepsis and septic shock?. *Semin Respir Crit Care Med.* 2021;42(5):650–61. <https://doi.org/10.1055/s-0041-1733915> PMID: [34544182](https://pubmed.ncbi.nlm.nih.gov/34544182/)
3. Daniels RC, Tiba MH, Cummings BC, Yap YR, Ansari S, McCracken BM, et al. Redox potential correlates with changes in metabolite concentrations attributable to pathways active in oxidative stress response in swine traumatic shock. *Shock.* 2022;57(6):282–90. <https://doi.org/10.1097/SHK.0000000000001944> PMID: [35670453](https://pubmed.ncbi.nlm.nih.gov/35670453/)
4. Daniels RC, Jun H, Tiba H, McCracken B, Herrera-Fierro P, Collinson M, et al. Whole blood redox potential correlates with progressive accumulation of oxygen debt and acts as a marker of resuscitation in a swine hemorrhagic shock model. *Shock.* 2018;49(3):345–51. <https://doi.org/10.1097/SHK.0000000000000933> PMID: [28658006](https://pubmed.ncbi.nlm.nih.gov/28658006/)
5. den Os MM, van den Brom CE, van Leeuwen ALI, Dekker NAM. Microcirculatory perfusion disturbances following cardiopulmonary bypass: a systematic review. *Crit Care.* 2020;24(1):218. <https://doi.org/10.1186/s13054-020-02948-w> PMID: [32404120](https://pubmed.ncbi.nlm.nih.gov/32404120/)
6. Fiaccadori E, Vezzani A, Coffrini E, Guariglia A, Ronda N, Tortorella G, et al. Cell metabolism in patients undergoing major valvular heart surgery: relationship with intra and postoperative hemodynamics, oxygen transport, and oxygen utilization patterns. *Crit Care Med.* 1989;17(12):1286–92. <https://doi.org/10.1097/00003246-198912000-00008> PMID: [2591223](https://pubmed.ncbi.nlm.nih.gov/2591223/)
7. Kalogeris T, Baines CP, Krenz M, Korthuis RJ. Ischemia/Reperfusion. In: Terjung R, editor. *Comprehensive Physiology.* 1st ed. Wiley; 2016. p. 113–170. <https://doi.org/10.1002/cphy.c160006> PMID: [28135002](https://pubmed.ncbi.nlm.nih.gov/28135002/)
8. Mertes P-M, Kindo M, Amour J, Baufretton C, Camilleri L, Caus T, et al. Guidelines on enhanced recovery after cardiac surgery under cardiopulmonary bypass or off-pump. *Anaesthesia Critical Care Pain Med.* 2022;41(3):101059. <https://doi.org/10.1016/j.accpm.2022.101059>
9. Ruffien-Ciszak A, Gros P, Comtat M, Schmitt A-M, Questel E, Casas C, et al. Exploration of the global antioxidant capacity of the stratum corneum by cyclic voltammetry. *J Pharm Biomed Anal.* 2006;40(1):162–7. <https://doi.org/10.1016/j.jpba.2005.05.035> PMID: [16137853](https://pubmed.ncbi.nlm.nih.gov/16137853/)
10. Bouchet J-B, Durand E, Morel J, Castelain C, Fuzellier J-F, Molliex S, et al. Microcirculatory dysfunction after cardiac surgery: interest of NIRS technology with two case reports. *Ann Fr Anesth Reanim.* 2011;30(7–8):589–93. <https://doi.org/10.1016/j.annfar.2011.04.008> PMID: [21602016](https://pubmed.ncbi.nlm.nih.gov/21602016/)
11. Murphy GS, Hessel EA 2nd, Groom RC. Optimal perfusion during cardiopulmonary bypass: an evidence-based approach. *Anesth Analg.* 2009;108(5):1394–417. <https://doi.org/10.1213/ane.0b013e3181875e2e> PMID: [19372313](https://pubmed.ncbi.nlm.nih.gov/19372313/)
12. Barry AE, Chaney MA, London MJ. Anesthetic management during cardiopulmonary bypass: a systematic review. *Anesth Analg.* 2015;120(4):749–69. <https://doi.org/10.1213/ANE.0000000000000612> PMID: [25790208](https://pubmed.ncbi.nlm.nih.gov/25790208/)
13. Dong G-H, Wang C-T, Li Y, Xu B, Qian J-J, Wu H-W, et al. Cardiopulmonary bypass induced microcirculatory injury of the small bowel in rats. *World J Gastroenterol.* 2009;15(25):3166–72. <https://doi.org/10.3748/wjg.15.3166> PMID: [19575498](https://pubmed.ncbi.nlm.nih.gov/19575498/)
14. Sakaki K, Kitamura T, Kohira S, Torii S, Mishima T, Hanayama N, et al. Regional thigh tissue oxygen saturation during cardiopulmonary bypass predicts acute kidney injury after cardiac surgery. *J Artif Organs.* 2020;23(4):315–20. <https://doi.org/10.1007/s10047-020-01175-y> PMID: [32448955](https://pubmed.ncbi.nlm.nih.gov/32448955/)
15. Rao SK, Palazzo RS, Metz HN, Wilson DW, Nikolic SD, Graver M, et al. Redox potential measurements of plasma in patients undergoing coronary artery bypass graft and its clinical significance. *J Pharmacol Toxicol Methods.* 1997;38(3):151–6. [https://doi.org/10.1016/s1056-8719\(97\)00080-4](https://doi.org/10.1016/s1056-8719(97)00080-4) PMID: [9523768](https://pubmed.ncbi.nlm.nih.gov/9523768/)
16. Rimachi R, Bruzzi de Carvahlo F, Orellano-Jimenez C, Cotton F, Vincent JL, De Backer D. Lactate/pyruvate ratio as a marker of tissue hypoxia in circulatory and septic shock. *Anaesth Intensive Care.* 2012;40(3):427–32. <https://doi.org/10.1177/0310057X1204000307> PMID: [22577907](https://pubmed.ncbi.nlm.nih.gov/22577907/)
17. Nikitas N, Kopterides P, Ilias I, Theodorakopoulou M, Vassiliadi DA, Armaganidis A, et al. Elevated adipose tissue lactate to pyruvate (L/P) ratio predicts poor outcome in critically ill patients with septic shock: a microdialysis study. *Minerva Anesthesiol.* 2013;79(11):1229–37. PMID: [23857439](https://pubmed.ncbi.nlm.nih.gov/23857439/)
18. Zoremba N, Homola A, Rossaint R, Syková E. Interstitial lactate, lactate/pyruvate and glucose in rat muscle before, during and in the recovery from global hypoxia. *Acta Vet Scand.* 2014;56(1):72. <https://doi.org/10.1186/s13028-014-0072-0> PMID: [25391249](https://pubmed.ncbi.nlm.nih.gov/25391249/)
19. Mallat J, Rahman N, Hamed F, Hernandez G, Fischer M-O. Pathophysiology, mechanisms, and managements of tissue hypoxia. *Anaesth Crit Care Pain Med.* 2022;41(4):101087. <https://doi.org/10.1016/j.accpm.2022.101087> PMID: [35462083](https://pubmed.ncbi.nlm.nih.gov/35462083/)
20. Mustafa I, Roth H, Hanafiah A, Hakim T, Anwar M, Siregar E, et al. Effect of cardiopulmonary bypass on lactate metabolism. *Intensive Care Med.* 2003;29(8):1279–85. <https://doi.org/10.1007/s00134-003-1860-6> PMID: [12845428](https://pubmed.ncbi.nlm.nih.gov/12845428/)
21. Saemann L, Wenzel F. Cutaneous microcirculation during operations with a cardiopulmonary bypass. *Clin Hemorheol Microcirc.* 2018;69(1–2):13–21. <https://doi.org/10.3233/CH-189102> PMID: [29630531](https://pubmed.ncbi.nlm.nih.gov/29630531/)
22. Rojas-Morales P, Pedraza-Chaverri J, Tapia E. Ketone bodies, stress response, and redox homeostasis. *Redox Biol.* 2020;29:101395. <https://doi.org/10.1016/j.redox.2019.101395> PMID: [31926621](https://pubmed.ncbi.nlm.nih.gov/31926621/)

23. Suzuki M, Suzuki M, Sato K, Dohi S, Sato T, Matsuura A, et al. Effect of beta-hydroxybutyrate, a cerebral function improving agent, on cerebral hypoxia, anoxia and ischemia in mice and rats. *Jpn J Pharmacol.* 2001;87(2):143–50. <https://doi.org/10.1254/jjp.87.143> PMID: [11700013](https://pubmed.ncbi.nlm.nih.gov/11700013/)
24. Genserová L, Duška F, Krajčová A.  $\beta$ -hydroxybutyrate exposure restores mitochondrial function in skeletal muscle satellite cells of critically ill patients. *Clin Nutr.* 2024;43(6):1250–60. <https://doi.org/10.1016/j.clnu.2024.04.009> PMID: [38653008](https://pubmed.ncbi.nlm.nih.gov/38653008/)
25. Liu G, Wang MQ, Kagawa T, Wada S, Morita S, Ohno Y, et al. Effects of extracorporeal circulation on blood ketone body ratio reflecting hepatic energy metabolism during cardiac operation. *Surg Gynecol Obstet.* 1993;177(5):507–12. PMID: [8211604](https://pubmed.ncbi.nlm.nih.gov/8211604/)
26. Levy B, Sadoune LO, Gelot AM, Bollaert PE, Nabet P, Larcan A. Evolution of lactate/pyruvate and arterial ketone body ratios in the early course of catecholamine-treated septic shock. *Crit Care Med.* 2000;28(1):114–9. <https://doi.org/10.1097/00003246-200001000-00019> PMID: [10667509](https://pubmed.ncbi.nlm.nih.gov/10667509/)
27. Hajjar LA, Almeida JP, Fukushima JT, Rhodes A, Vincent J-L, Osawa EA, et al. High lactate levels are predictors of major complications after cardiac surgery. *J Thorac Cardiovasc Surg.* 2013;146(2):455–60. <https://doi.org/10.1016/j.jtcvs.2013.02.003> PMID: [23507124](https://pubmed.ncbi.nlm.nih.gov/23507124/)
28. Lee Y-J, Park C-H, Yun J-W, Lee Y-S. Predictive comparisons of procalcitonin (PCT) level, arterial ketone body ratio (AKBR), APACHE III score and multiple organ dysfunction score (MODS) in systemic inflammatory response syndrome (SIRS). *Yonsei Med J.* 2004;45(1):29–37. <https://doi.org/10.3349/ymj.2004.45.1.29> PMID: [15004865](https://pubmed.ncbi.nlm.nih.gov/15004865/)
29. Murkin JM. Monitoring and optimization of the microcirculation during CPB. *J Thorac Dis.* 2019;11(Suppl 10):S1489–91. <https://doi.org/10.21037/jtd.2019.02.100> PMID: [31293798](https://pubmed.ncbi.nlm.nih.gov/31293798/)
30. Hernandez G, Bellomo R, Bakker J. The ten pitfalls of lactate clearance in sepsis. *Intensive Care Med.* 2019;45(1):82–5. <https://doi.org/10.1007/s00134-018-5213-x> PMID: [29754310](https://pubmed.ncbi.nlm.nih.gov/29754310/)
31. Nashef SAM, Roques F, Sharples LD, Nilsson J, Smith C, Goldstone AR, et al. EuroSCORE II. *Eur J Cardiothorac Surg.* 2012;41(4):734–44; discussion 744–5. <https://doi.org/10.1093/ejcts/ezs043> PMID: [22378855](https://pubmed.ncbi.nlm.nih.gov/22378855/)
32. Xu F, Li W, Zhang C, Cao R. Performance of sequential organ failure assessment and simplified acute physiology score II for post-cardiac surgery patients in intensive care unit. *Front Cardiovasc Med.* 2021;8:774935. <https://doi.org/10.3389/fcvm.2021.774935> PMID: [34938790](https://pubmed.ncbi.nlm.nih.gov/34938790/)
33. Guo Z, Tian Y, Liu N, Chen Y, Chen X, Yuan G, et al. Mitochondrial stress as a central player in the pathogenesis of hypoxia-related myocardial dysfunction: new insights. *Int J Med Sci.* 2024;21(13):2502–9. <https://doi.org/10.7150/ijms.99359> PMID: [39439461](https://pubmed.ncbi.nlm.nih.gov/39439461/)